A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Exact Sciences Corp stock. As of the latest transaction made, Citadel Advisors LLC holds 496,100 shares of EXAS stock, worth $28.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
496,100
Previous 390,900 26.91%
Holding current value
$28.8 Million
Previous $16.5 Million 104.54%
% of portfolio
0.01%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$42.43 - $70.83 $19.1 Million - $31.9 Million
-450,613 Reduced 97.67%
10,729 $730,000
Q2 2024

Aug 14, 2024

SELL
$41.33 - $74.26 $65.8 Million - $118 Million
-1,592,855 Reduced 77.54%
461,342 $19.5 Million
Q1 2024

May 15, 2024

SELL
$56.27 - $73.77 $38.6 Million - $50.6 Million
-685,487 Reduced 25.02%
2,054,197 $142 Million
Q4 2023

Feb 14, 2024

BUY
$59.06 - $75.72 $61.6 Million - $79 Million
1,043,452 Added 61.52%
2,739,684 $203 Million
Q3 2023

Nov 14, 2023

SELL
$65.94 - $99.04 $49.2 Million - $73.8 Million
-745,502 Reduced 30.53%
1,696,232 $116 Million
Q2 2023

Aug 14, 2023

BUY
$62.68 - $95.05 $47.7 Million - $72.4 Million
761,728 Added 45.34%
2,441,734 $229 Million
Q1 2023

May 15, 2023

BUY
$47.19 - $70.77 $20.5 Million - $30.8 Million
434,876 Added 34.93%
1,680,006 $114 Million
Q4 2022

Feb 14, 2023

SELL
$30.35 - $53.15 $1.98 Million - $3.47 Million
-65,193 Reduced 4.98%
1,245,130 $61.6 Million
Q3 2022

Nov 14, 2022

SELL
$31.97 - $49.37 $39 Million - $60.2 Million
-1,219,387 Reduced 48.2%
1,310,323 $42.6 Million
Q2 2022

Aug 15, 2022

BUY
$35.61 - $76.23 $89.4 Million - $191 Million
2,509,427 Added 12372.07%
2,529,710 $99.6 Million
Q1 2022

May 16, 2022

SELL
$57.56 - $82.54 $13.6 Million - $19.5 Million
-236,699 Reduced 92.11%
20,283 $1.42 Million
Q4 2021

Feb 14, 2022

SELL
$72.5 - $100.68 $23 Million - $31.9 Million
-317,189 Reduced 55.24%
256,982 $20 Million
Q3 2021

Nov 15, 2021

BUY
$90.24 - $124.05 $43.3 Million - $59.5 Million
479,305 Added 505.24%
574,171 $54.8 Million
Q2 2021

Aug 16, 2021

BUY
$93.66 - $139.27 $413,321 - $614,598
4,413 Added 4.88%
94,866 $11.8 Million
Q1 2021

May 17, 2021

SELL
$116.57 - $155.01 $9.42 Million - $12.5 Million
-80,849 Reduced 47.2%
90,453 $11.9 Million
Q4 2020

Feb 16, 2021

SELL
$99.61 - $142.12 $12.6 Million - $17.9 Million
-126,007 Reduced 42.38%
171,302 $22.7 Million
Q3 2020

Nov 16, 2020

SELL
$72.92 - $102.01 $61.2 Million - $85.5 Million
-838,623 Reduced 73.83%
297,309 $30.3 Million
Q2 2020

Aug 14, 2020

BUY
$55.75 - $92.75 $53.4 Million - $88.8 Million
957,741 Added 537.48%
1,135,932 $98.8 Million
Q1 2020

May 15, 2020

BUY
$37.9 - $104.44 $3.15 Million - $8.69 Million
83,228 Added 87.64%
178,191 $10.3 Million
Q4 2019

Feb 14, 2020

SELL
$77.66 - $99.74 $31.7 Million - $40.8 Million
-408,591 Reduced 81.14%
94,963 $8.78 Million
Q3 2019

Nov 14, 2019

BUY
$90.37 - $122.49 $34.2 Million - $46.3 Million
377,934 Added 300.85%
503,554 $45.5 Million
Q2 2019

Aug 14, 2019

BUY
$89.51 - $118.04 $8.06 Million - $10.6 Million
90,087 Added 253.53%
125,620 $14.8 Million
Q1 2019

May 15, 2019

SELL
$61.98 - $96.5 $12.9 Million - $20.1 Million
-207,876 Reduced 85.4%
35,533 $0
Q4 2018

Feb 14, 2019

BUY
$56.04 - $82.66 $11.2 Million - $16.5 Million
199,297 Added 451.8%
243,409 $15.4 Million
Q3 2018

Nov 13, 2018

SELL
$48.29 - $80.6 $37 Million - $61.7 Million
-765,952 Reduced 94.55%
44,112 $0
Q2 2018

Aug 10, 2018

BUY
$37.84 - $69.96 $22.1 Million - $40.9 Million
584,144 Added 258.56%
810,064 $0
Q1 2018

May 11, 2018

BUY
$39.82 - $57.53 $3.1 Million - $4.48 Million
77,944 Added 52.67%
225,920 $9.11 Million
Q4 2017

Feb 09, 2018

SELL
$46.49 - $60.51 $1.57 Million - $2.04 Million
-33,674 Reduced 18.54%
147,976 $7.78 Million
Q3 2017

Nov 09, 2017

BUY
$37.05 - $47.12 $6.73 Million - $8.56 Million
181,650
181,650 $8.56 Million

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.3B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.